RenalSense
- Company typePrivate
- Founded2009
- HeadquartersJerusalem, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
RenalSense firmographics
Firmographics- Name
- RenalSense
- Website
- https://renalsense.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
RenalSense industry classification
Industry- Product category
- Critical Care Medical Diagnostics
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ)
- akta.pro secondary industries
- Acute Kidney Injury (AKI) & Hospital Nephrology (Inpatient Consults) (HLAKAHAI), Critical Care Nephrology (ICU/CRRT Services) (HLAKAHAN)
Keywords
Where RenalSense is headquartered
LocationHeadquarters
- HQ city
- Jerusalem
- HQ country
- Israel
- HQ region
- Middle East
Markets served
RenalSense business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
RenalSense product offering
Product offeringCore offering
RenalSense develops a real-time diagnostic platform for the detection, prevention, and management of Acute Kidney Injury (AKI) in critical care settings. The platform is deployed in intensive care units (ICUs) to continuously monitor kidney function and enable early clinical intervention.
Differentiator
Problem solved
Functional benefit
Products and services
- Real-Time AKI Diagnostic Platform for Critical Care
Companies that use RenalSense
Customer profileIdeal customer profiles1 record
RenalSense technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
RenalSense partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights4 records
RenalSense competitors and assessment
Company assessmentDirect peers
- Astute Medical (a bioMérieux company): Developed NephroCheck, the leading FDA-cleared AKI biomarker test, now owned by bioMérieux. Direct competitor in the AKI diagnostics category, addressing the same ICU clinical problem with a biomarker rather than a real-time device approach.
- Potrero Medical (acquired by Medtronic): Developed the Accuryn system, a real-time urine output monitoring device for ICU AKI prediction — the closest functional analog to RenalSense's real-time platform. Now part of Medtronic's patient monitoring portfolio.
- BioPorto Diagnostics: Commercializes The NGAL Test for early AKI detection. Competes in the same AKI diagnostic category via biomarker-based testing for critically ill patients.
Emerging players
- Sphingotec: Developer of penKid (proenkephalin), an emerging blood-based biomarker for real-time AKI risk assessment. Competes with RenalSense in delivering earlier AKI signals in critical care.
- Outset Medical: Developer of the Tablo hemodialysis system used in both hospital and home settings. Comparable as a renal-focused technology challenger attempting to disrupt established renal care workflows.
Broad incumbents
- bioMérieux: Global in vitro diagnostics leader and parent of Astute Medical/NephroCheck. A dominant incumbent in the renal diagnostic space with established hospital sales channels RenalSense must contend with.
- Medtronic: Global medtech incumbent with the Potrero/Accuryn AKI monitoring asset plus a broad critical care portfolio. Competes on hospital formulary, evidence generation, and integrated ICU platforms.
- Edwards Lifesciences: Critical care monitoring leader with the FloTrac/HemoSphere platforms for hemodynamically compromised ICU patients — adjacent to AKI risk monitoring and a potential integrated competitor in the ICU.
- Fresenius Medical Care: World's largest dialysis services and products company, with deep nephrology relationships and growing interest in remote/AKI monitoring. Sets the competitive bar for renal care commercialization at scale.
- Baxter International: Diversified medtech with a renal care franchise (dialysis machines, CRRT, peritoneal dialysis) and active interest in earlier-stage kidney injury management in the ICU.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
RenalSense social profiles
Digital presenceRenalSense financial estimates
Financial estimateRevenue estimate
Valuation estimate
RenalSense leadership team
Management profileNumber of profiles
Profiles1 record
RenalSense funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RenalSense M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RenalSense
What does RenalSense do?
RenalSense develops a real-time diagnostic platform for the detection, prevention, and management of Acute Kidney Injury (AKI) in critical care settings. The platform is deployed in intensive care units (ICUs) to continuously monitor kidney function and enable early clinical intervention.
Is RenalSense a public or private company?
RenalSense is a private company. It is classified as venture growth investor backed and is currently operating.
When was RenalSense founded?
RenalSense was founded in 2009. It employs 11 to 50 people.
Where is RenalSense based?
RenalSense is headquartered in Jerusalem, Israel, in the Middle East region.
Who are RenalSense's main competitors?
Direct peers on record are Astute Medical (a bioMérieux company), Potrero Medical (acquired by Medtronic) and BioPorto Diagnostics. Emerging players are Sphingotec and Outset Medical. Broad incumbents are bioMérieux, Medtronic, Edwards Lifesciences, Fresenius Medical Care and Baxter International.
Does RenalSense have an API?
No public API is recorded for RenalSense.
What industry is RenalSense in?
RenalSense's product category is Critical Care Medical Diagnostics. Its primary akta.pro industry code is HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status), with a secondary code of HLAKAHAI, Acute Kidney Injury (AKI) & Hospital Nephrology (Inpatient Consults). Its SIC code is 3841.